SUMMARY We studied the in vitro effect of indomethacin, hydrocortisone, sulphasalazine, and its metabolites sulphapyridine (SP) and 5-amino salicylic acid (5-ASA) on peripheral blood mononuclear cells (PBMC) from 49 patients with inflammatory bowel disease and 34 controls. Indomethacin caused a highly significant increase in the PBM.C response to the mitogen PHA-P compared with controls (p < 0.01), indicating increased activity of a prostaglandin-producing suppressor cell system. On the contrary, sulphasalazine resulted in a reduced response which was significantly great-r for the group with inflammatory bowel disease than the control group (p <0.05). This reduction was also produced by 5-ASA (p <005) but not by sulphapyridine. Addition of indomethacin to PBMC incubated with sulphasalazine significantly reduced the effect of sulphasalazine (P <O001). Hydrocortisone resulted in a reduced response which was similar to that of controls and was not altered by the addition of indomethacin. The response to indomethacin, hydrocortisone, sulphasalazine, sulphapyridine, and 5-ASA was not dependent on the HLA type of the patients, disease activity, or drug therapy. The results suggest that increased suppression by a population of prostaglandinproducing suppressor cells plays a role in the immunopathology of inflammatory bowel disease, but that sulphasalazine does not exert its therapeutic effect by acting on this step of the immunoregulatory system. Any trials of indomethacin therapy in inflammatory bowel disease should take into account that, in vitro, sulphasalazine and indomethacin have opposing mechanisms of action in this system.
The discovery of increased levels of prostaglandinlike material in rectal biopsy material1-4 and in the faecal content5 of patients with inflammatory bowel disease has led to suggestions for a possible role for prostaglandins in the pathogenesis of the disease6.
Reports of the beneficial effect of indomethacin in conditions such as post-radiation colitis7, food allergies8, and irritable bowel disease" have stimulated further interest in the effects of prostaglandin synthetase inhibitors in inflammatory bowel disease. Similarly, although the mode of action of sulphasalazine is unknown, it has been postulated that sulphasalazine itself may act as a prostaglandin synthetase inhibitor6.
After the description of prostaglandin producing suppressor cells, sensitive to indomethacin10, in a variety of conditions including sarcoidosis"l and Hodgkin's disease12, we have used this system to study the in vitro effect of indomethacin, hydrocortisone, and sulphasalazine and its metabolites 
Results
Thirty-four patients with Crohn's disease, 15 patients with ulcerative colitis, and 34 controls were studied. Twenty-five of the patients had active disease and 24 were in remission. Eleven were taking sulphasalazine alone, 19 prednisone alone, and 18 were on no treatment. The remaining patient was taking both drugs. The results of the response to PHA-P, Con-A, PWM, and the effects of indomethacin, sulphasalazine, sulphapyridine, and 5-ASA are shown in Table 1 and Fig. 1 . There was a significant reduction in the response of PBMC to PHA-P in Crohn's disease compared with controls (p < 0.05) but otherwise there was no difference between controls, and patients with Crohn's disease or ulcerative colitis in the response to the other mitogens.
As illustrated in Table 1 and Fig. 2 , there was a highly significant increase in the response to indomethacin, indicating increased prostaglandinproducing cell activity in the Crohn's disease group (13*47 % ±23 1) and ulcerative colitis group (7.8 % ± and 5-ASA were -11.7%±11.4, -1166%±8-5, and -11.9 %± 16.1 respectively and these results were similar to those obtained in the normal controls and significantly less than those in inflammatory bowel disease for both sulphasalazine and 5-ASA (p < 0.05). Table 2 shows the results obtained in patients grouped according to disease activity and drug therapy. There was no significant difference between these groups. The response to hydrocortisone, sulphasalazine, sulphapyridine, and 5-ASA from patients with a positive in vitro response to indomethacin was similar to that from patients with a (Table 3) . Thirty of the patients had been HLA A and B typed, and we were able to evaluate the effects of indomethacin with reference to HLA types in these patients. We looked specifically at those that were B12 positive (n = 7) and compared them with those who were B8 positive (n=6) and those who were positive to neither of these antigens (n=17). Results were 124%±60, 12.8%± 14.6 and 14.2%±29.9 for the three groups. These values were not significantly different from one another. Finally, we studied the effect of adding sulphasalazine and indomethacin at the same time on the PHA-P response in 16 patients (Fig. 3) 
Discussion
We have shown that patients with inflammatory bowel disease have increased indomethacinsensitive, prostaglandin-producing suppressor cells compared with the control group. This is consistent with, and could explain, the known mild reduction in the lymphocyte response to mitogens in patients with inflammatory bowel disease"3 14. Although we did not investigate this in our patients, previous studies have shown that this suppressor cell is probably a prostaglandin-producing monocyte9ll-, data compatible with the growing number of reports group.bmj.com on December 23, 2017 -Published by http://gut.bmj.com/ Downloaded from of 'activated macrophages' in inflammatory bowel disease'5. Whether the increased activity of this suppressor cell system in inflammatory bowel disease is primary and of importance immunopathogenetically, or is an epiphenomenon cannot be determined from this study. The observation that levels were similar in patients with active or quiescent disease suggests that it is primary, although its occurrence in other conditions" 12 suggests that it may be a secondary phenomenon. We failed to confirm the suggestion, based on studies in normal controls, that this system is HLAdependent'6.
Our results suggest that neither sulphasalazine nor corticosteroids exert their therapeutic effect by affecting this limb of the immunoregulatory system. The results might explain the increased levels of prostaglandins that have been found in rectal biopsies in patients with inflammatory bowel disease, as it may be macrophages and not the colonic epithelial cells which produce the prostaglandins. The presence of increased prostaglandin-producing suppressor cell activity suggests a possible role for indomethacin in patients with inflammatory bowel disease and provides additional justification for trials with drugs such as indomethacin, although the observation that concurrent incubation of PBMC with indomethacin and sulphasalazine reduces the effects of sulphasalazine suggests that these two drugs may have antagonistic, although possibly unrelated, modes of action6. Indeed, sulphasalazine may act on the monocyte and influence lymphocyte response, possibly by prostaglandin release. Thus, in clinical trials the effect of indomethacin on patients not concurrently taking sulphasalazine should receive special attention. It should also be remembered that, if the increased PgSS is a compensatory response, then blocking it with indomethacin may have a detrimental effect.
Reports have suggested that sulphasalazine may inhibit prostaglandin synthetases5' . Our results do not support this, but suggest that it has an immunosuppressant effect which is not dependent on the response to indomethacin. Furthermore, this in vitro effect of indomethacin is not blocked by coincubation with sulphasalazine. Corticosteroids are also thought to have antiprostaglandin properties, possibly by reducing the availability of substrate for prostaglandin synthesis'7. The in vitro response to hydrocortisone that we observed does not support the suggestion that the main therapeutic role of corticosteroids in inflammatory bowel disease is to reduce prostaglandin synthesis. The coincubation experiments are difficult to interpret but suggest that hydrocortisone, sulphasalazine, and indomethacin all have different modes of activity.
In our view, it is of interest that the reduction of lymphocyte response caused by sulphasalazine is greater in patients with inflammatory bowel disease than in controls, particularly as its effect seemed to be most marked for its metabolite 5-ASA, which appears to be the active metabolitel8s20 and is not seen with sulphapyridine. However, the difference is small and previous work on the effect of sulphasalazine on lymphocyte responses has failed to show this specificity in inflammatory bowel disease21-23. Although our finding needs to be confirmed by others, the results are compatible with the hypothesis that sulphasalazine acts on the monocyte which is known to circulate in increased numbers in inflammatory bowel disease.
The response to mitogens of patients receiving sulphasalazine was not reduced compared with those on no treatment. This might argue against an immunosuppressant effect, but nor was there a significant reduction in patients on corticosteroids, which is known to be a potent immunosuppressant. Drug levels of sulphasalazine are particularly high in colonic mucosa and it may be that a local immunosuppressant effect accounts for the beneficial effect of the drug.
In conclusion, the results suggest that there is an increased population of prostaglandin-producing suppressor cells in inflammatory bowel disease, which may play a role in the immunopathogenesis of the disease. There is no evidence in this system that sulphasalazine acts as a prostaglandin synthetase inhibitor. Trials of indomethacin in inflammatory bowel disease will help to determine whether this suppressor cell system is of immunopathogenic importance but should take into account the possibility that indomethacin and sulphasalazine have different and possibly antagonistic modes of action in vivo as well as in vitro. These findings are supported by recent studies on gastrointestinal smooth muscle24 which also show that the two drugs have opposite effects. Supported in part by USPHS grant GCRC RRI09 and the Gastrointestinal Vermont Education and Research Fund. Sulphasalazine, sulphapyridine, and 5-amino salicylic acid were kindly supplied by Pharmacia Laboratories and indomethacin by Merck, Sharp and Dohme Research Laboratories. G H is in receipt of a Fulbright Travelling Fellowship.
